Logo

DMAAU

Drugs Made In America Acquisition Corp. Units

DMAAU

Drugs Made In America Acquisition Corp. Units • NASDAQ
$10.49 ▲ 0.00% (+0.00)
Market Cap $245.78 M
52w High $10.82
52w Low $10.00
Dividend Yield 0%
P/E 0
Volume 97
Outstanding Shares 23.43M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $263.703K ▲ $2.185M ▼ 0% $0.07 ▲ $0 ▲
Q2-2025 $0 $131.919K ▼ $2.289M ▲ 0% $0.068 ▼ $-131.919K ▲
Q1-2025 $0 $330.925K ▲ $1.255M ▲ 0% $130.51 ▲ $-330.925K ▼
Q4-2024 $0 $279.875 ▼ $-279 ▲ 0% $-0.033 ▼ $0 ▲
Q3-2024 $0 $144.928K $-144.928K 0% $-0.005 $-144.928K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $717 ▼ $237.632M ▲ $7.357M ▲ $-7.328M ▼
Q2-2025 $822 ▼ $235.206M ▲ $7.201M ▼ $228.004M ▲
Q1-2025 $923 ▼ $232.806M ▲ $7.247M ▲ $225.559M ▲
Q4-2024 $1.351K ▼ $550.824 ▼ $795.669 ▼ $-244 ▲
Q3-2024 $2.095K $426.139K $590.998K $-164.859K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $785.092K ▼ $137.908K ▲ $231.15M ▲ $-231.304M ▼ $-105 ▲ $137.904K ▲
Q2-2025 $3.688M ▲ $-300.671K ▼ $-231.15M $231.466M ▲ $-1.273K ▼ $-300.669K ▼
Q1-2025 $1.255M ▲ $-251.244K ▼ $-231.15M ▼ $231.401M ▲ $-428 ▲ $-251.244K ▼
Q4-2024 $-279 ▲ $-106 ▲ $0 $-638 ▼ $-744 ▲ $-123 ▲
Q3-2024 $-144.928K $-57.228K $0 $41.225K $-16.003K $-57.23K

Five-Year Company Overview

Income Statement

Income Statement DMAAU is a newly formed SPAC, so its income statement is not that of an operating business. It has essentially no revenue and only modest costs related to forming, listing, and running the shell company, which show up as a small loss per share. There is no underlying product, customer base, or operating margin to analyze yet; all of that will depend on the company it eventually acquires.

Balance Sheet

Balance Sheet The balance sheet information provided is largely placeholder and not very informative, which is common at this very early stage. In practice, a SPAC like DMAAU typically holds most of its assets as cash or cash-like securities from the funds it has raised, with relatively simple liabilities and shareholder equity. Since there is no operating business yet, there are no meaningful inventories, fixed assets, or working capital dynamics to review. The real shape of the balance sheet will only emerge after a merger with a target company.

Cash Flow

Cash Flow Current cash flows are driven almost entirely by financing activities and routine corporate expenses, not by business operations. Cash is mainly raised through the SPAC’s IPO and then preserved in a trust, while operating cash outflows tend to consist of professional fees, legal work, and administrative costs. There is no real capital spending or growth investment pattern to interpret yet, because those will come only once DMAAU completes a business combination.

Competitive Edge

Competitive Edge As a SPAC, DMAAU has no direct competitive position in a product market; its differentiation is in its theme and its team. The stated mission is to back a company that brings more drug manufacturing back to the United States, tapping into concerns about supply chain security and reliance on foreign producers. The leadership and advisors combine experience in pharmaceuticals, large-scale agriculture, retail health, and finance, which could help in identifying and scaling a suitable target. The main competitive risk is that many other buyers are also seeking attractive healthcare and pharmaceutical assets, which can make finding and closing a strong deal challenging.

Innovation and R&D

Innovation and R&D DMAAU itself does not conduct research and development; its role is to find a company that already has meaningful technology and a defensible position. The target is likely to focus on advanced, domestically based drug manufacturing, potentially using modern production technologies, improved drug delivery methods, and more resilient sourcing of ingredients. Any real innovation “moat” will come from the acquired firm’s patents, regulatory track record, manufacturing know-how, and distribution relationships, not from DMAAU as a shell. Until a specific deal is announced, all innovation potential remains conceptual rather than observable.

Summary

DMAAU is a blank-check vehicle with minimal standalone financial substance and no operating history; its value and risk profile hinge entirely on the quality of the company it eventually acquires. The strategy is tightly aligned with a major policy and industry theme: shifting more pharmaceutical production back to the United States to improve supply chain security. Strengths include a clearly articulated mission and a leadership group with relevant but diverse backgrounds spanning pharma, health retail, agriculture, and finance. Key uncertainties are whether DMAAU can secure a high-quality target on reasonable terms, how long that will take, and how well the combined business will execute in a highly regulated and competitive pharmaceutical landscape. Market observers will likely focus less on current financial statements and more on any future merger announcement, the target’s technology, its competitive moat, and its ability to scale domestic drug production effectively.